Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66,577,393
-
Total 13F shares
-
24,079,194
-
Share change
-
-2,557,426
-
Total reported value
-
$222,960,463
-
Put/Call ratio
-
323%
-
Price per share
-
$9.26
-
Number of holders
-
70
-
Value change
-
-$69,848,932
-
Number of buys
-
50
-
Number of sells
-
40
Institutional Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q1 2021
As of 31 Mar 2021,
Cardiff Oncology, Inc. - Common Stock (CRDF) was held by
70 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,079,194 shares.
The largest 10 holders included
JANUS HENDERSON GROUP PLC, Corriente Advisors, LLC, Avidity Partners Management LP, CAXTON CORP, EVENTIDE ASSET MANAGEMENT, LLC, VANGUARD GROUP INC, CITADEL ADVISORS LLC, Artal Group S.A., TWO SIGMA INVESTMENTS, LP, and Octagon Capital Advisors LP.
This page lists
70
institutional shareholders reporting positions in this security
for the Q1 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.